cardin one power player along
updat forecast estim
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research may
estim
price data may
rate updat may
currenc amount express
valuat growth profit
methodolog valu compani
stand elit player within healthcar
market believ firm possess wide econom moat
abl turn signific size market share key
competit advantag cardin critic cogs within
pharmaceut industri mani supply-chain particip
depend servic streamlin product distribut
procur expect use pharmaceut increas
next sever year provid solid platform
cardin continu success
cardin third-largest pharmaceut distributor revenu
main supplier retail pharmaci network
firm also suppli sever larg provid gpo mass
retail razor-thin profit contract
enorm amount capit need build top-tier global drug
wholesaling/distribut oper
competit foundat cardin larg kept new
entrant bay
cardin also made strateg move believ
benefici long term one sign agreement
caremark two firm combin gener
sourc oper allow opportun enhanc
profit combin sourc entiti abl garner
greater price discount gener manufactur
howev enthusiast cardin recent push
medic equip manufactur distribut although
healthcar spend growth continu exceed growth
case low-tech medic surgic product
gener experi market growth low singl digit
believ asset could suppress roic detract valu
firm top-tier core drug distribut oper
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
cardin health major distributor pharmaceut medic
suppli pharmaci hospit oper includ procur
packag inventori manag logist servic largest
custom retail pharmaci oper
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
cardin report disastr quarter medic
chicken come roost cardin report
disastr quarter larg driven cordi medic
decreas profit lower ep guidanc
remaind year result loss eman
medic suppli busi develop
major neg say least surpris
issu firm face within segment last
quarter firm hint could headwind
horizon cordi busi issu seem
fulli matur
howev cardin remain strong long-term posit
within pharmaceut market
reiter wide moat rate also incorpor
latest result dcf model like
lower fair valu margin howev even
lower valuat anticip stock remain
under-valued materi amount
previous state enthusiast
cardin push medic equip manufactur
distribut although global healthcar spend
remain robust forese futur case
low-tech medic surgic product
gener commod addit think cordi
product necessarili top tier within
categori believ cardin may
decreas price order preserv volum pressur
profit fear dynam would eventu
develop cardin long neg toward
previou capit alloc polici nondrug
ultim look altern strategi
cardin recent divestitur under-perform chines
drug oper combin quarter develop
solidifi neg outlook firm ancillari
busi believ previou manag team
strategi drive growth expand outsid core
wide-moat drug distribut oper incorrect
cours materi impair econom return
new manag team state begun process
reevalu aspect enterpris look
reset strategi said believ best
cours action firm would divest much
medic suppli oper share much
synergi wide-moat drug distribut oper
perspect firm focu optim
drug wholes oper look instead expand
specialti pharmaceut oper
even huge disappoint quarter likelihood
continu headwind cardin next
quarter believ posit critic cogs within
global pharmaceut suppli chain provid
opportun produc signific econom profit
long term thu major sell-off stock price would
opportun investor long-term time horizon
acquir wide-moat busi signific discount
valuat growth profit may
lower fair valu estim cardin
given struggl within medic suppli
busi lower near- long-term profit
forecast firm medic suppli segment
also factor moder higher tax rate next
year captur tax issu firm face certain
region abl total off-set loss
cordi unit addit factor restructur
charg next two year believ manag
like implement busi realign plan
refocu firm econom profit gener
oper also account firm gener
sourc partnership believ add
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
pharmaceut market growth effect redoak
sourc jv ultim outcom
restructur medic suppli segment bull-cas
scenario factor less price profit
pressur also assum cardin abl exert even
negoti leverag given gener sourc
partnership also assum medic suppli
busi recov expect along drug
spend growth enhanc return addit factor
high-single-digit drug industri growth uptak
drug usag increas faster initi expect
scenario fair valu estim increas
bear case assum effort bring regulatori
price pressur industri succeed addit
assum gener sourc partnership
advantag firm medic suppli segment
continu value-destruct also assum secular
industri growth driver fail materi par current
expect scenario fair valu estim
decreas
believ three major pharmaceut wholesal
possess wide econom moat turn
coloss size key competit advantag
retail outlet solidifi long-term competit
posit accord center medicar
medicaid servic estim total amount retail
pharmaceut spend unit state close
billion major spend flow
oper
distributor domin drive robust sustain
econom profit player
major
estim
combin market share well
materi bottom line along acquisit
harvard drug believ two oper tactic
yield excel roic next sever year offset
posit action firm recent medic devic
manufactur busi believ provid
distribut fall outsid cardin core drug
distribut oper drag core
boost posit firm-specif outlook posit
age popul influx previous
uninsur peopl healthcar market greater
use pharmaceut front-lin treatment provid
platform solid top- bottom-lin growth
accordingli factor five-year revenu
compound-annual-growth-rate averag oper margin explicit
scenario analysi take consider effect
potenti price control supplier price pressur
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
combin dynam slim industri profit keep new
entrant bay new player would tough time
carv enough share effici leverag
distribut asset posit econom profit
dynam solidifi long-term wide econom moat
major three drug distributor firm also abl
obtain signific price discount
drug
manufactur mani custom acquir
make essenti cogs
allow build excel asset effici effect rout
infrastructur
unparallel logist expertis driven decent asset
return howev abil effect manag
capit base true driver outsiz return cardin
firm abl produc top-tier asset turn cash
convers inventori manag metric
led outsiz roic trend believ last
believ cardin stabl econom moat trend
given tailwind highli favor demograph trend
expans government-sponsor healthcar
coverag uninsur firm abl
leverag solid pharmaceut spend next
pharmaceut industri main sourc drug suppli
signific portion retail pharmaci outlet
effici distributor drug manufactur
excel econom
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
ocardin one three major pharmaceut
wholesal close billion
advantag drug manufactur
revenu size posit
opharmaceut spend grow solid clip
next decad given demograph shift
expans medic insur coverag
specialti drug spend continu increas
believ distributor opportun captur
valu nich market grow bottom
oprofit margin cardin razor-thin make
effort procur cheaper suppli gener
product cardin partner
enhanc negoti power fixed-cost scale
partnership fail outlook futur revenu
profit growth take hit
ocardin shown propens acquir non-core
busi order drive growth believ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
cardin rel solid financi health firm
cash flow healthcare-rel oper provid
solid foundat long-term financi stabil capit
leverag increas materi fund two
third billion acquisit patient
recoveri busi debt howev firm strong
cash gener allow easili pay debt
see cardin current
debt/ebitda ratio fall next sever year
reach end five-year explicit forecast period
cardin face three main risk push stricter
regul pharmaceut industri player increas
price pressur payer push outsid core
drug wholes activ concert
effort certain healthcar market stakehold
feder govern enact price control drug
sold distributor acquisit cost becom
greater result could hurt cardin return
addit payer sought curb growth drug
spend last year believ trend
remain place sever year manufactur
retail pharmaci custom unwil budg
current price demand cardin profit could
squeez final cardin move drive growth
expand non-core busi
medic device/consumable-product manufactur
distribut believ market lucr
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
ceo januari replac georg barrett
serv head posit sinc
move slightli surpris come shock
given recent struggl cardin barrett almost
decad set overal strategi drug
wholesal kaufmann held plethora role firm
cours year tenur prior becom ceo
serv cardin cfo led mani firm
major divis believ deep knowledg everi
aspect cardin serv well overal chief
overal believ stewardship cardin fair
oper execut capit manag
larg benefici sharehold believ
trend chang kaufmann leadership
repres date owner name posit common share held report holder issuer
fidel manag research compani
share
fund
share
fund
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
cardin report disastr quarter medic
chicken come roost cardin report
disastr quarter larg driven cordi medic
decreas profit lower ep guidanc
remaind year result loss eman
medic suppli busi develop
major neg say least surpris
issu firm face within segment last
quarter firm hint could headwind
horizon cordi busi issu seem
fulli matur
howev cardin remain strong long-term posit
within pharmaceut market
reiter wide moat rate also incorpor
latest result dcf model like
lower fair valu margin howev even
lower valuat anticip stock remain
under-valued materi amount
previous state enthusiast
cardin push medic equip manufactur
distribut although global healthcar spend
remain robust forese futur case
low-tech medic surgic product
gener commod addit think cordi
product necessarili top tier within
categori believ cardin may
decreas price order preserv volum pressur
profit fear dynam would eventu
develop cardin long neg toward
previou capit alloc polici nondrug
ultim look altern strategi
cardin recent divestitur under-perform chines
drug oper combin quarter develop
solidifi neg outlook firm ancillari
busi believ previou manag team
strategi drive growth expand outsid core
wide-moat drug distribut oper incorrect
cours materi impair econom return
new manag team state begun process
reevalu aspect enterpris look
reset strategi said believ best
cours action firm would divest much
medic suppli oper share much
synergi wide-moat drug distribut oper
perspect firm focu optim
drug wholes oper look instead expand
specialti pharmaceut oper
even huge disappoint quarter likelihood
continu headwind cardin next
quarter believ posit critic cogs within
global pharmaceut suppli chain provid
opportun produc signific econom profit
long term thu major sell-off stock price would
opportun investor long-term time horizon
acquir wide-moat busi signific discount
cardin report in-lin quarter drug
distribut segment fiscal first quarter howev
issu seem abat second-quart
firm abl leverag gener sourc
partnership lower gener drug cost
howev firm face issu within medic
product busi price pressur ineffici
within cordi oper pressur profit
firm result quarter stellar believ
reflect wholesal long-term
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
posit accordingli reiter wide moat
rate fair valu estim firm
pressur firm core pharmaceut segment
past quarter reset gener
portfolio price past year mani independ
pharmaci client demand lower gener price
respect pharmaceut wholesal cardin
re-price materi portion group purchas
contract result firm success offset
gener price headwind quarter
obtain lower sourc cost red oak joint
ventur believ develop highlight
power posit cardin built sourc
partnership valu produc next
sever year even posit develop
firm central cost increas segment
manag state made materi level
invest enhanc effici distribut
asset perspect invest pay
next year given secular trend flow
entir healthcar market
nevertheless concern regard firm
medic product segment price pressur
central cost issu aros quarter specif
manag call medic glove product cost
ineffici within cordi oper main
antagonist surpris develop
fall line thesi segment although
healthcar spend growth continu exceed
growth case low-tech medic
surgic product gener experi market
growth low singl digit develop
quarter heighten concern believ medic
product segment could suppress return invest capit
detract valu firm top-tier core drug
disrupt pbm mco wholesal jan
amazon berkshir hathaway jpmorgan
announc jan trio form independ
healthcar compani help control healthcar cost
 -base employe could
potenti given capit clout three partner
believ certain investor underappreci
moati natur healthcar suppli chain
formid competit advantag insul
signific headwind tri break vertic along
chain dynam healthcar market
difficult navig specul amazon
berkshir jp disrupt space leverag
impress capit war chest busi expertis
caus valuat pbm mco drug wholesal
retail pharmaci fall materi believ
stock price creat
opportun investor acquir solid wide-moat firm
discount would highlight express script
cardin particularli good
exact oper structur products/servic
ultim mandat partnership yet
develop partnership tri
sizabl corpor busi without major
chang within healthcar marketplac capit
manag clout three partner undoubtedli
great howev core-compet healthcar
relat take signific time legitim
oper develop addit believ potenti
new partnership would lack scale size provid
effici price power par major
healthcar servic firm especi case given
local densiti necessari obtain decent provid price
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
sourc joint ventur among retail pharmaci
drug distributor pharmaci benefit manag
combin number employe firm
close million initi may seem like give
partnership signific price power howev even
firm abl leverag entir million-person
employe base would pale comparison larg
healthcar servic firm equival small/mid-
tier insur estim combin number cover
live five major mco approxim
million live three larg pbm million
live respect thu price power new
partnership would garner significantli lower
healthcar servic firm built addit
mani employe trio base intern
hous independ oper like bring
total number one million potenti cover live
regul legal requir need effici
deliv healthcar extrem oner
absolut need consum safeti
would new entrant need compli variou feder
agenc claim regulatori jurisdict healthcar
servic product also countless state
municip foreign agenc licens regulatori
approv would take year new partnership fulli
compliant abl provid full-servic healthcar
servic employe administr work
wait period would also add signific time
regulatori approv process perspect amazon
berkshir jp new entrant healthcar
market would need partner one three larg
pbm one five larg mco order viabl
player within space
overview drug suppli chain would highlight
recent report sell drug easier said done
moati pharma channel analyz potenti
new competit within pharmaceut market
analysi wide moat exist space
cardin report challeng quarter announc
chang manag
near-term issu pressur cardin oper
environ firm report challeng fiscal first
quarter result howev headwind
expect deviat near-term outlook
firm also announc ceo year georg barrett
step end year hand rein
mike kaufmann cardin current cfo believ
firm recent struggl shift healthcar market may
motiv move believ kaufmann
extens experi within cardin integr role
play drive oper financi
strategi firm make solid choic take
top role
firm result quarter stellar
believ reflect wholesal long-term
posit accordingli reiter wide moat
rate fair valu estim cardin pressur
firm core pharmaceut segment reset
gener portfolio price last year mani
independ pharmaci client demand lower
gener price respect pharmaceut
wholesal cardin two main rival amerisourc
re-price materi portion
group purchas contract result believ
somewhat lag trend cardin
result quarter peer
even though gener price major near-term
issu cardin believ consid
long-term driver valu firm perspect
current gener deflat issu relat custom contract
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
price work issu
come decad firm match
distribut effici near-term gener
price influenc extrapol long
term accordingli believ downsid market
overreact would push firm equiti materi
fair valu estim would provid investor
opportun acquir share high-qual busi
advantag price
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end june
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
